Reviewer's report

Title: Osteonecrosis of the jaw - a rare side effect of annual bisphosphonate administrations for osteoporosis?: a case report

Version: 2 Date: 17 June 2011

Reviewer: Thomas Mücke

Which of the following best describes what type of case report this is?: Unreported or unusual side effects or adverse interactions involving medications

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: No

Is this case worth reporting?: No

Is the case report persuasive?: Yes

Does the case report have explanatory value?: No

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

The authors present a case report of BRONJ in a patient with oral BP intake due to osteoporosis. Although studies already exist about the occurrence of BRONJ in such patients, the very low but common dosage of zoledronic acid and alendronate is remarkable in this case report. The author clearly stated this special fact and pointed out the role of BP in osteoporosis management. The discussion is adequate and informative. I would like to ask the authors how, as they stated, is it possible to clearly differentiate histopathologically between osteonecrosis due to BP intake and osteomyelitis/osteonecrosis due to infection? Did the author use special methods to discriminate or has the diagnosis mainly confirmed by clinical signs?
Quality of written English: Acceptable

Declaration of competing interests:
I declare that I have no competing interests.